Overview
Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive malignancy predominantly affecting adolescent and young adult males. Characterized by its desmoplastic stroma and small round cells, DSRCT often presents with abdominal masses or peritoneal involvement, leading to significant morbidity and mortality. Due to its rarity and aggressive nature, early recognition and appropriate management are crucial for improving patient outcomes. Understanding the molecular underpinnings and clinical nuances of DSRCT is essential for clinicians to tailor effective treatment strategies and provide optimal care 12.Pathophysiology
DSRCT arises from a characteristic chromosomal translocation, most commonly EWSR1-WT1, which fuses the EWSR1 gene with the WT1 gene. This fusion leads to aberrant transcriptional regulation, driving the expression of genes involved in cell proliferation and survival, such as IGF2 and FGFR4, which are highly expressed in these tumors 1. The EWS-WT1 fusion protein also impacts cellular differentiation pathways, contributing to the undifferentiated nature of the tumor cells. At the cellular level, these genetic alterations result in uncontrolled proliferation and resistance to apoptosis, forming the dense desmoplastic stroma characteristic of DSRCT. The molecular complexity further implicates immune evasion mechanisms, suggesting potential targets for immunotherapy 1.Epidemiology
DSRCT is exceedingly rare, with an estimated annual incidence of less than 1 per million individuals globally. It predominantly affects males, with a median age at diagnosis around 15 to 20 years, though cases in adults have been reported 2. Geographic distribution does not suggest specific regional clustering, but data are limited due to the rarity of the disease. Trends over time indicate no significant change in incidence, highlighting the persistent challenge in diagnosing and treating this malignancy 2.Clinical Presentation
Patients with DSRCT often present with nonspecific symptoms due to the tumor's location and extent. Common manifestations include abdominal pain, palpable masses, and signs of bowel obstruction or organ dysfunction secondary to mass effect. Systemic symptoms like weight loss, fatigue, and fever may also occur, reflecting the aggressive nature of the disease. Red-flag features include rapid progression, peritoneal spread, and involvement of multiple organs, necessitating prompt diagnostic evaluation to confirm the diagnosis and initiate treatment 34.Diagnosis
The diagnosis of DSRCT involves a combination of clinical, radiological, and histopathological assessments. Key steps include:Imaging Studies: CT and MRI scans are crucial for identifying the extent of disease, particularly in the abdomen and pelvis. Ultrasonography can also play a role in initial detection and characterization of intra-abdominal masses 3.
Biopsy and Histopathology: Definitive diagnosis relies on histopathological examination. Characteristic features include small round cells embedded in a dense fibrous stroma. Immunohistochemistry is pivotal, with strong positivity for markers such as WT1, desmin, and CD15, while negativity for markers like cytokeratin 5/6 and neural markers helps differentiate from other small round cell tumors 4.
Molecular Testing: Confirmation of the EWSR1-WT1 translocation through fluorescence in situ hybridization (FISH) or next-generation sequencing is essential for definitive diagnosis 1.Specific Criteria and Tests:
Immunohistochemistry: Positive for WT1, desmin, CD15; negative for cytokeratin 5/6, neurofilament proteins.
Molecular Analysis: Presence of EWSR1-WT1 fusion confirmed by FISH or NGS.
Differential Diagnosis: Distinguish from other small round cell tumors such as neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma based on immunohistochemical profiles and molecular findings 4.Differential Diagnosis
Neuroblastoma: Typically positive for synaptophysin and chromogranin, often seen in younger children.
Rhabdomyosarcoma: Positive for myogenin and myoD1, more common in soft tissues.
Ewing Sarcoma: Characterized by EWSR1 translocations but different fusion partners (e.g., FLI1), distinct immunohistochemical profile.Management
First-Line Treatment
Surgical Resection: When feasible, complete resection of the primary tumor can improve outcomes. However, due to the aggressive nature and frequent metastatic spread, complete resection is often challenging 2.
Chemotherapy: Multi-agent chemotherapy regimens are standard, often including ifosfamide, etoposide, and vincristine. Specific protocols may vary based on institutional experience and patient factors 2.Specific Regimens:
Ifosfamide + Etoposide: Commonly used, tailored dosing based on patient tolerance.
Vincristine: Often included in combination regimens.Second-Line and Refractory Disease
Radiation Therapy: Considered for palliation of symptoms or in cases where surgical resection is incomplete. Commonly used for localized disease or to manage complications like bowel obstruction 2.
Targeted Therapies: Emerging evidence suggests potential benefits from targeting pathways like IGF2 and FGFR4, though specific agents are still under investigation 1.Specific Approaches:
Radiation: High-dose external beam radiation for symptomatic relief or local control.
Targeted Agents: Clinical trials exploring FGFR inhibitors and other molecularly targeted therapies are recommended for refractory cases 1.Contraindications
Severe Renal Impairment: Certain chemotherapeutic agents may need dose adjustments or avoidance.
Severe Hepatic Dysfunction: Monitoring and dose modifications are necessary for agents metabolized by the liver.Complications
Peritoneal Spread: Leads to bowel obstruction and abdominal pain, requiring surgical intervention or palliative care.
Metastatic Disease: Commonly involves distant organs, necessitating systemic therapy adjustments.
Treatment-Related Toxicity: Significant myelosuppression, mucositis, and neurotoxicity from chemotherapy necessitate close monitoring and supportive care. Referral to oncology specialists is crucial for managing these complications 2.Prognosis & Follow-Up
The prognosis for DSRCT remains poor, with median overall survival (OS) around 25.9 months, significantly influenced by stage at diagnosis and extent of disease 2. Prognostic indicators include advanced stage, lack of surgical resection, and presence of metastatic disease. Regular follow-up includes imaging studies (CT/MRI) every 3-6 months for the first two years, followed by less frequent assessments based on clinical stability. Monitoring for recurrence and managing late effects of therapy are essential components of long-term care 2.Special Populations
Pediatric Patients: While DSRCT predominantly affects adolescents, pediatric cases exist with similar aggressive behavior but may require tailored pediatric-specific chemotherapy regimens.
Adults: Management strategies often mirror pediatric approaches, though adult patients may have different comorbidities influencing treatment tolerance and choice 2.Key Recommendations
Confirm Diagnosis with Molecular Testing: Utilize FISH or NGS to detect EWSR1-WT1 fusion for definitive diagnosis (Evidence: Strong 1).
Multi-Agent Chemotherapy: Employ regimens including ifosfamide, etoposide, and vincristine as first-line therapy (Evidence: Moderate 2).
Surgical Resection When Feasible: Attempt complete resection of the primary tumor to improve outcomes (Evidence: Moderate 2).
Consider Radiation Therapy for Symptomatic Relief: Use high-dose radiation for palliation in advanced or unresectable cases (Evidence: Moderate 2).
Monitor for Treatment Toxicity: Regularly assess for myelosuppression, mucositis, and neurotoxicity, adjusting supportive care as needed (Evidence: Moderate 2).
Evaluate for Targeted Therapies: Consider clinical trials involving FGFR inhibitors and other molecularly targeted agents in refractory cases (Evidence: Weak 1).
Aggressive Follow-Up: Schedule imaging and clinical assessments every 3-6 months for the first two years post-treatment (Evidence: Expert opinion).
Manage Complications Proactively: Address peritoneal spread and metastatic disease with multidisciplinary approaches (Evidence: Expert opinion).
Tailor Treatment Based on Patient Age and Comorbidities: Adjust chemotherapy regimens considering pediatric or adult-specific factors (Evidence: Expert opinion).
Promote Supportive Care: Integrate psychological and palliative care to support quality of life (Evidence: Expert opinion).References
1 Hingorani P, Dinu V, Zhang X, Lei H, Shern JF, Park J et al.. Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children's Oncology Group. Scientific reports 2020. link
2 Gani F, Goel U, Canner JK, Meyer CF, Johnston FM. A national analysis of patterns of care and outcomes for adults diagnosed with desmoplastic small round cell tumors in the United States. Journal of surgical oncology 2019. link
3 N'Dri K, Aguéhoundé C, Konan A, Ouattara ND, Abby CB. [Intra-abdominal small round-cell desmoplastic tumor: ultrasonographic and computed tomographic aspects. Apropos of a case]. Journal de radiologie 1998. link
4 Ordóñez NG. Desmoplastic small round cell tumor: II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. The American journal of surgical pathology 1998. link